19837-74-2Relevant articles and documents
Design, solvent-free synthesis and antibacterial activity evaluation of new coumarin sulfonamides
Aminarshad, Farzaneh,Heidari, Shima,Mostajeran, Neda,Massah, Ahmad Reza
, p. 547 - 562 (2021/08/16)
A simple cost-effective and green method was presented for the synthesis of coumarin bis sulfonamides. Seventeen novel coumarin sulfonamides were synthesized in good to high yield and purity in six steps starting from 2-amino thiazole, aniline, and 4-methoxy aniline. All of the reactions have been done under green conditions without using any hazardous solvent. The chemical structures of the products were elucidated by IR, 1H NMR, and 13C NMR spectroscopy and elemental analysis. Also, the anti-bacterial properties of the synthesized sulfonamides were investigated using two strains of Staphylococcus (gram-positive) and Escherichia coli (gram-negative) bacteria.
Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27
Blavier, Jeremy,Charles, Ma?lle,Hanson, Julien,Kronenberger, Thales,Laschet, Céline,Müller, Christa E.,Pillaiyar, Thanigaimalai,Rosato, Francesca,Wozniak, Monika
, (2021/08/27)
GPR27 belongs, with GPR85 and GPR173, to a small subfamily of three receptors called “Super-Conserved Receptors Expressed in the Brain” (SREB). It has been postulated to participate in key physiological processes such as neuronal plasticity, energy metabolism, and pancreatic β-cell insulin secretion and regulation. Recently, we reported the first selective GPR27 agonist, 2,4-dichloro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (I, pEC50 6.34, Emax 100%). Here, we describe the synthesis and structure-activity relationships of a series of new derivatives and analogs of I. All products were evaluated for their ability to activate GPR27 in an arrestin recruitment assay. As a result, agonists were identified with a broad range of efficacies including partial and full agonists, showing higher efficacies than the lead compound I. The most potent agonist was 4-chloro-2,5-difluoro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (7y, pEC50 6.85, Emax 37%), and the agonists with higher efficacies were 4-chloro-2-methyl-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (7p, pEC50 6.04, Emax 123%), and 2-bromo-4-chloro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (7r, pEC50 5.99, Emax 123%). Docking studies predicted the putative binding site and interactions of agonist 7p with GPR27. Selected potent agonists were found to be soluble and devoid of cellular toxicity within the range of their pharmacological activity. Therefore, they represent important new tools to further characterize the (patho)physiological roles of GPR27.
Benzsulfamide IDO1 inhibitor, and preparation method and application thereof
-
Paragraph 0152-0156, (2017/08/29)
The invention belongs to the field of drugs, and particularly relates to a benzsulfamide compound having a structural characteristic as shown in formula (I) or pharmaceutically acceptable salt of the benzsulfamide compound, a preparation method of the benzsulfamide compound or the salt, and uses of the benzsulfamide compound or the salt as an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. An experimental result indicates that the compound provided by the invention has an obvious inhibiting effect on the activity of the IDO1, can effectively promote T cell proliferation, inhibits native T cells from differentiating into regulatory T cells, reverses immunosuppression mediated by the IDO1, and can be used for treating relevant diseases having pathological characteristics of metabolic pathways of kynurenine mediated by the IDO1, including cancer, virus infection, neurodegenerative diseases, cataract, organ transplant rejection, depression, autoimmune diseases and the like. Formula (I) is shown in the description.
